灾难性血栓瘤:一个叙事审查
Massimo Franchini1, Daniele Focosi2, Mario Piergiulio Pezzo1
1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy.
Seminars in thrombosis and hemostasis
|August 16, 2024
概括
灾难性血栓症涉及广泛的血栓,是医疗紧急情况. 早期识别和治疗潜在原因以及抗凝药对患者的生存至关重要.
科学领域:
- 血液学 血液学 血液学
- 关键护理医学 关键护理医学
- 内部医学 内部医学
背景情况:
- 灾难性血栓塞是一种罕见但危及生命的疾病,其特点是高凝血状态和多重血栓栓塞事件.
- 它与各种疾病有关,包括灾难性抗脂综合征,血栓性微血管病变,癌症和感染.
- 血栓风暴需要紧急医疗干预,并带来了重大管理挑战.
研究的目的:
- 为了回顾灾难性血栓塞的主要特征.
- 分析可能引发这种严重并发症的各种情况.
- 为受影响患者提供诊断和初始管理算法.
主要方法:
- 这项研究是一种叙事性审查.
- 它综合了有关灾难性血栓塞的病理生理学和临床表现的信息.
- 提出了一个用于诊断和管理的算法.
主要成果:
- 灾难性血栓瘤呈现出高凝血倾向和多重血栓栓塞事件的快速发作.
- 相关的条件是多样化的,突出需要广泛的差异诊断.
- 及时的抗凝剂和潜在原因的识别/治疗是改善预后的关键.
结论:
- 灾难性血栓塞是关键的医疗紧急情况,需要迅速和全面的管理.
- 早期诊断和针对性治疗导致因素对于患者的治疗结果至关重要.
- 拟议的算法旨在指导医生对这种疾病进行检查和初步治疗.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Disorders of Hemostasis
758
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
758
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
Clot Retraction and Fibrinolysis
5.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.0K
Extrinsic and Intrinsic Pathways of Hemostasis
6.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.6K


